$CLNN News

Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS

HC Wainwright & Co. Reiterates Buy on Clene, Maintains $31 Price Target

Clene Submits New Drug Application To FDA For Accelerated Approvla Of CNM-Au8

Clene Targets Q4 FDA Filing for ALS Drug CNM-Au8, Eyes Mid-2027 Decision

Clene to Present at Upcoming Investor Conferences

Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDA

Clene Announces $4 Million Registered Direct Offering

Clene Prices Registered Direct Offering Of 1,219,513 Shares At $3.28/Shr To Existing Shareholders With Total Gross Proceeds Of $4M

Clene to Present at Upcoming September Investor Conferences

Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses

Clene to Present at the Emerging Growth Conference

Clene Inc. (CLNN) Reports Q2 Loss, Beats Revenue Estimates

Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights

Clene Targets Early Q4 NDA Filing for CNM-Au8 in ALS

Clene to Present at The Canaccord 46th Annual Growth Conference

Clene (CLNN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Clene Reports First Quarter 2026 Financial Results and Recent Operating Highlights

Clene Q1 EPS $(0.69) Misses $(0.66) Estimate, Sales $15.000K Miss $35.064K Estimate

Clene Conference: CEO Says FDA Minutes Suggest CNM-Au8 Data Could Support ALS NDA Filing

HC Wainwright & Co. Reiterates Buy on Clene, Maintains $31 Price Target